Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances
Tala Al Tabosh, … , Sophie Dupuis-Girod, Sabine Bailly
Tala Al Tabosh, … , Sophie Dupuis-Girod, Sabine Bailly
Published February 15, 2024
Citation Information: J Clin Invest. 2024;134(4):e176379. https://doi.org/10.1172/JCI176379.
View: Text | PDF
Review Series

Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances

  • Text
  • PDF
Abstract

Hereditary hemorrhagic telangiectsia (HHT) is an inherited vascular disorder with highly variable expressivity, affecting up to 1 in 5,000 individuals. This disease is characterized by small arteriovenous malformations (AVMs) in mucocutaneous areas (telangiectases) and larger visceral AVMs in the lungs, liver, and brain. HHT is caused by loss-of-function mutations in the BMP9-10/ENG/ALK1/SMAD4 signaling pathway. This Review presents up-to-date insights on this mutated signaling pathway and its crosstalk with proangiogenic pathways, in particular the VEGF pathway, that has allowed the repurposing of new drugs for HHT treatment. However, despite the substantial benefits of these new treatments in terms of alleviating symptom severity, this not-so-uncommon bleeding disorder still currently lacks any FDA- or European Medicines Agency–approved (EMA-approved) therapies.

Authors

Tala Al Tabosh, Mohammad Al Tarrass, Laura Tourvieilhe, Alexandre Guilhem, Sophie Dupuis-Girod, Sabine Bailly

×

Figure 1

AVMs: The hallmark of HHT and its clinical consequences.

Options: View larger image (or click on image) Download as PowerPoint
AVMs: The hallmark of HHT and its clinical consequences.
In HHT, focal d...
In HHT, focal dilations of the postcapillary venules (indicated on images by V) progressively encompass the normal capillaries and establish a direct connection with dilated arterioles (indicated by A), leading to AVM formation, muscularization of large vessels, and dilation of capillary beds, which are often surrounded by inflammatory cells. At the microvascular level, AVMs appear as telangiectases on specific mucocutaneous areas (finger pads, lips, tongue, nasal and digestive mucosa). They are responsible for spontaneous and recurrent epistaxis/bleeding, leading to bleeding iron-deficiency anemia. At the macrovascular level, large AVMs mainly affect the liver, leading to high-output cardiac failure, and more rarely biliary ischemia and portal hypertension; lung AVMs can provoke ischemic stroke and cerebral abscess and, more rarely, hypoxemia and hemoptysis. Central nervous system AVM is rarely complicated by hemorrhage. Skin and liver sections were stained for H&E. Photo of the liver section was provided by J.Y. Scoazec (Institut Gustave Roussy, University Paris-Saclay, Paris, France).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts